Organogenesis Holdings (STU:2PQ) Beneish M-Score: -2.63 (As of Jun. 26, 2026)


STU:2PQ Organogenesis Holdings Inc STU:2PQ
67 GF Score
Price €2.12
GF Value €2.76
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Beneish M-Score?

Organogenesis Holdings STU:2PQ -0.93% 67 Beneish M-Score is -2.63 as of Jun. 26, 2026. GuruFocus rates STU:2PQ with a GF Score™ of 67/100 and a GF Value™ of €2.76 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 911 Drug Manufacturers companies, Organogenesis Holdings ranks better than 62.02% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.63 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Organogenesis Holdings's Beneish M-Score or its related term are showing as below:

STU:2PQ' s Beneish M-Score Range Over the Past 10 Years
Min: -215.54   Med: -2.32   Max: -1.18
Current: -2.63

During the past 11 years, the highest Beneish M-Score of Organogenesis Holdings was -1.18. The lowest was -215.54. And the median was -2.32.


Organogenesis Holdings Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Beneish M-Score Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.72 -2.53 -2.84 -1.99 -1.38

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.18 -1.86 -1.31 -1.38 -2.63

STU:2PQ vs SIGA, ELTP, TKNO: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Beneish M-Score falls into.


STU:2PQ
67GF Score
Organogenesis Holdings Inc STU:2PQ
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Organogenesis Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0262+0.528 * 1.0429+0.404 * 0.9682+0.892 * 1.0311+0.115 * 1.0761
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9715+4.679 * -0.045717-0.327 * 1.2525
=-2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €101.1 Mil.
Revenue was 31.356 + 192.211 + 128.215 + 87.375 = €439.2 Mil.
Gross Profit was 9.063 + 149.581 + 97.329 + 63.42 = €319.4 Mil.
Total Current Assets was €232.3 Mil.
Total Assets was €449.8 Mil.
Property, Plant and Equipment(Net PPE) was €136.5 Mil.
Depreciation, Depletion and Amortization(DDA) was €28.4 Mil.
Selling, General, & Admin. Expense(SGA) was €273.9 Mil.
Total Current Liabilities was €65.8 Mil.
Long-Term Debt & Capital Lease Obligation was €52.9 Mil.
Net Income was -45.98 + 37.32 + 18.375 + -8.143 = €1.6 Mil.
Non Operating Income was 0.033 + -1.74 + -0.77 + -1.45 = €-3.9 Mil.
Cash Flow from Operations was 18.275 + 33.665 + 2.623 + -28.501 = €26.1 Mil.
Total Receivables was €95.6 Mil.
Revenue was 80.191 + 120.956 + 103.774 + 120.987 = €425.9 Mil.
Gross Profit was 58.247 + 91.303 + 79.631 + 93.862 = €323.0 Mil.
Total Current Assets was €248.0 Mil.
Total Assets was €432.3 Mil.
Property, Plant and Equipment(Net PPE) was €103.9 Mil.
Depreciation, Depletion and Amortization(DDA) was €23.6 Mil.
Selling, General, & Admin. Expense(SGA) was €273.4 Mil.
Total Current Liabilities was €60.2 Mil.
Long-Term Debt & Capital Lease Obligation was €30.9 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(101.125 / 439.157) / (95.571 / 425.908)
=0.230271 / 0.224394
=1.0262

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(323.043 / 425.908) / (319.393 / 439.157)
=0.758481 / 0.727287
=1.0429

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (232.253 + 136.514) / 449.793) / (1 - (248.048 + 103.853) / 432.339)
=0.180141 / 0.186053
=0.9682

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=439.157 / 425.908
=1.0311

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(23.634 / (23.634 + 103.853)) / (28.412 / (28.412 + 136.514))
=0.185384 / 0.172271
=1.0761

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(273.869 / 439.157) / (273.396 / 425.908)
=0.623624 / 0.641913
=0.9715

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((52.884 + 65.758) / 449.793) / ((30.872 + 60.174) / 432.339)
=0.26377 / 0.210589
=1.2525

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1.572 - -3.927 - 26.062) / 449.793
=-0.045717

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Organogenesis Holdings has a M-score of -2.70 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.63 mean?
Organogenesis Holdings (STU:2PQ) has a Beneish M-Score of -2.63 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Organogenesis Holdings and its competitors. According to the industry distribution chart, Organogenesis Holdings ranks #346 out of 911 companies in the Drug Manufacturers industry, placing it in the top 38%.
Is Organogenesis Holdings' Beneish M-Score too high?
Organogenesis Holdings' current Beneish M-Score is -2.63. Based on the distribution chart, Organogenesis Holdings ranks #346 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Beneish M-Score compare to SIGA and ELTP?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #346 out of 911 companies for Beneish M-Score. This puts Organogenesis Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Organogenesis Holdings and its competitors. Organogenesis Holdings's current Beneish M-Score is -2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (STU:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.76, compared to a current price of €2.12 — trading 23.2% below its estimated fair value. The current Beneish M-Score is -2.63. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Organogenesis Holdings (STU:2PQ), the current Beneish M-Score is -2.63 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of €2.12 is trading 23.2% below its estimated GF Value™ of €2.76. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for STU:2PQ:

  • Beneish M-Score: -2.63
  • GF Value™: €2.76 vs. price of €2.12 (23.2% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organogenesis Holdings Business Description

Other Exchanges ORGO:USA2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for STU:2PQ

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.12
Price
€2.76
GF Value